The tweet was deleted by the author.
But we saved everything 🙂.
Editas Medicine will attend the 94th European Atherosclerosis Society Congress in Athens next week, where it plans to present new preclinical findings on its lead in vivo development candidate, EDIT-401.
The company aims to highlight advancements in therapies targeting atherosclerosis, with EDIT-401 positioned at the center of its latest research efforts. Attendees can expect detailed updates on the candidate's preclinical performance and strategic implications for future clinical development.
View post on X Loading...
Editas Medicine has recently shared plans to present new preclinical data on its gene editing technologies at major scientific conferences, focusing on cardiovascular research initiatives such as EDIT-401 earlier this year. The company also released its first quarter 2026 results with a business update detailing progress in its gene editing programs last month. These updates provide additional context for Editas' strategy in advancing in vivo therapies.